Skip to main content
Clinical Trials/NCT04905342
NCT04905342
Completed
Phase 1

An Open-label, Randomized, Evaluate the Pharmacokinetics and the Safety of NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers

NVP Healthcare1 site in 1 country58 target enrollmentAugust 14, 2021

Overview

Phase
Phase 1
Intervention
NVP-1805
Conditions
Healthy Volunteers
Sponsor
NVP Healthcare
Enrollment
58
Locations
1
Primary Endpoint
Pharmacokinetics of plasma: Cmax
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this study is to compare the pharmacokinetics of NVP-1805 and coadministration of NVP-1805-R1 with NVP-1805-R2.

Detailed Description

Evaluate pharmacokinetics and safety of NVP-1805 compared to coadministration of NVP-1805-R1 with NVP-1805-R2

Registry
clinicaltrials.gov
Start Date
August 14, 2021
End Date
January 7, 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
NVP Healthcare
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Healthy adult subjects who signed informed consent
  • BMI of \>18.0 kg/㎡ and \<30.0 kg/㎡ subject, weight more than 50kg(45 kg or more for woman)

Exclusion Criteria

  • Subjects participated in another clinical trial within 6 months prior to administration of the study drug
  • Inadequate subject for the clinical trial by the investigator's decision
  • Subjects participated in another clinical trial within 6 months prior to administration of the study drug

Arms & Interventions

NVP-1805

NVP-1805 (80/10/20.8mg)

Intervention: NVP-1805

NVP-1805-R1 and NVP-1805-R2

coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10/20.8mg)

Intervention: NVP-1805-R1and NVP-1805-R2

Outcomes

Primary Outcomes

Pharmacokinetics of plasma: Cmax

Time Frame: 0hours - 72hours

period 1,2,3,4

Pharmacokinetics of plasma: AUClast

Time Frame: 0hours - 72hours

period 1,2,3,4

Study Sites (1)

Loading locations...

Similar Trials